Trial Profile
A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients with Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs CB 103 (Primary)
- Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Anaplastic large cell lymphoma; Burkitt's lymphoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Dermatofibrosarcoma; Diffuse large B cell lymphoma; Fibroma; Follicular lymphoma; Gastrointestinal cancer; Glioblastoma; Haematological malignancies; Liposarcoma; Malignant melanoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Peripheral T-cell lymphoma; Prostate cancer; Rhabdomyosarcoma; Sarcoma; Solid tumours; T-cell lymphoma; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Cellestia Biotech
- 29 Sep 2023 This study has been completed in Netherland, according to European Clinical Trials Database record.
- 07 Feb 2023 Status changed from recruiting to discontinued.
- 04 Sep 2022 This trial has been Discontinued in Spain, according to European Clinical Trials Database record.